Related Experiment Videos
Development of an HIV-1-dependent expression vector with the Cre/loxP system
1Department of Industrial Chemistry, Chiba Institute of Technology, Narashino, Japan.
Nucleic Acids Symposium Series
|April 26, 2000
Summary
This study demonstrates a novel gene therapy approach for AIDS treatment. Hammerhead ribozymes, delivered via retroviral vectors, effectively suppressed HIV-1 replication and enabled site-specific viral DNA excision.
Area of Science:
- Molecular Biology
- Virology
- Gene Therapy
Background:
- Human immunodeficiency virus (HIV) infection remains a global health challenge.
- Developing effective antiviral strategies is crucial for managing AIDS.
- Previous work utilized tRNA promoters for hammerhead ribozyme expression against HIV-1.
Purpose of the Study:
- To investigate the potential of a Cre-loxP recombination system for molecular genetic intervention against HIV-1.
- To evaluate the efficacy of retroviral vectors expressing hammerhead ribozymes in suppressing HIV-1 replication.
Main Methods:
- Construction of VSV-G-pseudotyped MuLV-based vectors expressing hammerhead ribozymes targeting the HIV-1 LTR region.
- Infection of MT-4 cells with HIV-1 and assessment of gag p24 antigen production.
- Application of the Cre-loxP recombination system for site-specific HIV-1 excision.
Main Results:
- The ribozyme-expressing retroviral vector significantly suppressed gag p24 antigen production in acutely HIV-1 infected MT-4 cells.
- Site-specific excision of HIV-1 was successfully achieved using the Cre-loxP system in an acute infection model.
- These findings indicate a potent antiviral effect of the engineered ribozymes.
Conclusions:
- Hammerhead ribozymes delivered via retroviral vectors show strong potential for suppressing HIV-1 replication.
- The Cre-loxP system offers a promising strategy for site-specific excision of HIV-1 DNA.
- This research represents a significant step towards developing novel gene-based therapies for AIDS.